Natera, Inc. (NTRA)

Sector: Healthcare
Industry: Services-Medical Laboratories
Country: United States
Exchange: NASDAQ
Market cap: $39.64B
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Latest financial period: September 30, 2026
Filed with the SEC: November 5, 2026
Estimated earnings date: Not available
Profit #1267 of 1422 companies
| | Sep 26 | Jun 26 | Mar 26 | Dec 25 |
|---|
| ROE/ROA | 8.4% | 9.2% | 9.6% | 9.8% |
Growth #294 of 1422 companies
Payout #1089 of 1422 companies
Safety #80 of 1422 companies
Price #1285 of 1422 companies